【摘要】 ５６例以肺癌为主（５３例）实体瘤，化疗期并用甲孕酮（ＭＰＡ）２５０ｍｇ，２次／ｄ，共１５ｄ。单程或连续３程化疗（ＣＴ）并ＭＰＡ者，食量增加各为６７．９％及７８．６％（Ｐ＞０．０５）；体重平均增加２．２ｋｇ及４．３ｋｇ（Ｐ＞０．０５）。３３例ＣＴ期并或不并ＭＰＡ自身比较：单ＣＴ无１例食量增加，减少者５４．５％。并ＭＰＡ者，食量增加者６６．７％，无１例食量减少；二者体重增加各为１８．２％及６６．７％，平均增加吝为１．９ｋｇ及２．３ｋｇ。二者食量增加和无变化与食量减少比，差别极著（Ｐ＞０．００００…）：体重增加和无变化与体重减少比，差别亦著（Ｐ＜０．０１）。服ＭＰＡ期间７．１％伴轻度下肢浮肿，１７．４％伴阴道出血，均可逆性。更多还原

【Abstract】 For improving life quality,concomitant use of medroxyprogestrone acetate(MPA) was adapted in a daily dose of 500mg for a period of 15 days, in 56 cancer patients (53 lung cancer) receiving chemotherapy(CT).The rate of food intake increas-ing in patients who were given MPA in conjunction with CT, were 67.9%in the first course of treatment and 78.6%in continuous treatment to the third course. The corre-sponding average weight gained were 2.2kg and 4.3kg respectively,For self-comparison in 33 patients, at first they were treated alone with CT and treated concomitantly with MPA. Results were as following:regimen adapted weight gained food take in average in percentage %increment CT 1.9kg 18.2 54.5 CT+MPA2.3k9 66.7 66.7 The results showed that MPA plays an important role in improving the life quality of cancer patients receiving CT on the basis of food intake increatment and weight gained.更多还原